Ginkgo bioworks stocks.

DNA: Ginkgo Bioworks - Full Company Report. Get the latest Full Company Report for Ginkgo Bioworks from Zacks Investment Research

Ginkgo bioworks stocks. Things To Know About Ginkgo bioworks stocks.

Sep 17, 2021 · Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker ... Dec 4, 2023 · The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight. Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA) shareholders that were waiting for something to happen have been dealt a blow with a 30% share price drop in …stock market synthetic biology Ginkgo Bioworks The synthetic biology company went public less than a month ago through a $1.6 billion special purpose acquisition company deal, which bestowed upon ...

Discover historical prices for DNA stock on Yahoo Finance. View daily, weekly or monthly format back to when Ginkgo Bioworks Holdings, Inc. stock was issued.While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long-term projections.

Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.

Not a stock for the Oracle of Omaha (yet) For the uninitiated, Ginkgo Bioworks is a deeply innovative biotech that specializes in automating the design and cultivation of synthetic bacteria and fungi.Stock analysis for Ginkgo Bioworks Holdings Inc (DNA:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile.News ; 17.11.2023. 3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report ; 13.11.2023. 3 Cathie Wood Bargain Buys That Should Be on Your List Too ; 09.11 ...Sep 20, 2023 · On that note, on August 29 Ginkgo Bioworks ( DNA 5.80%) announced that it is joining forces with Alphabet, Google's parent company, in a five-year strategic partnership to develop and use new ...

stock market synthetic biology Ginkgo Bioworks The synthetic biology company went public less than a month ago through a $1.6 billion special purpose acquisition company deal, which bestowed upon ...

Ginkgo Bioworks Holdings Inc. analyst ratings, historical stock prices, earnings estimates & actuals. DNA updated stock price target summary.

It's not a stock for the faint of heart, but its ambitious vision might pay off. Wall Street Says Ginkgo Bioworks Stock Will Soar 132%, and Cathie Wood's Buying It. …The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and DNA history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines.Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock ...Ginkgo Bioworks Holdings Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%.Ginkgo Bioworks Holdings, Inc ... Buyers of the stock will need to have faith that Ginkgo can accelerate their business in the future as a PS of 12.5 for a company with operating margins of -228% ...Ginkgo Bioworks Holdings (NYSE: DNA) is owned by 57.45% institutional shareholders, 14.28% Ginkgo Bioworks Holdings insiders, and 28.27% retail investors. Cascade Investment LLC is the largest individual Ginkgo Bioworks Holdings shareholder, owning 151.87M shares representing 7.17% of the company.Ginkgo Bioworks went public two years ago via a special purpose acquisition company. Deep losses and significant cash burn have made investors wary of investing in this risky stock. Special ...

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended ...Evgenii Kovalev. Ginkgo Bioworks (NYSE:DNA) is still finding its feet as a public company, with the stock continuing to decline on the back of valuation concerns and declining Biosecurity revenue ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.3. Ginkgo Bioworks. Ginkgo Bioworks (DNA 10.85%) is a company that specializes in organisms, and this could be a major business well into the future as these specially engineered organisms help ...Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals.Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 …

Ginkgo Bioworks Holdings Inc’s stock is NA in 2023, NA in the previous five trading days and down 24.46% in the past year. Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% net profit margin. Year-over-year quarterly sales ...

Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you...When Ginkgo Bioworks co-founders Jason Kelly and Reshma Shetty each reported total compensation valued at $380.7 million in 2021, it turned some heads. ... Ginkgo’s stock price has slipped 65% ...Ginkgo Bioworks. Wood has dipped her toes into the nascent eTVOL industry, but she's already ankle-deep in Ginkgo Bioworks' (DNA-2.52%) biofoundry platform. After the company bought millions more ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.People have been waiting for this for a long time. And now it’s happening. People have been waiting for this for a long time. And now it’s happening. Money has started pouring out of the bond market. And more importantly, it’s pouring back ...Ginkgo Bioworks Holdings (NYSE: DNA) is owned by 57.45% institutional shareholders, 14.28% Ginkgo Bioworks Holdings insiders, and 28.27% retail investors. Cascade Investment LLC is the largest individual Ginkgo Bioworks Holdings shareholder, owning 151.87M shares representing 7.17% of the company.Ginkgo Bioworks Company Info. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and ... Jan 13, 2023 ... Ginkgo is down over 85% from its peak, to $1.84 per share. Its $23 billion valuation has shrunk to $2.81 billion, quickly ending Kelly's brief ...The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and DNA history to help you invest and trade smarter. Menu icon A vertical stack of three evenly spaced horizontal lines.

The Ark Invest CEO is also known for having a bit of a contrarian streak, buying shares of stocks right as the market is dumping them, which is exactly what she's doing with Ginkgo Bioworks ( DNA ...

Ginkgo Bioworks Holdings, Inc. (DNA) NYSE - Nasdaq Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.4200 +0.1300 (+10.08%) As of 03:32PM EST. Market open. 1d.

Ginkgo Bioworks ( DNA -7.19%) is a biotech that's operating on multiple bleeding edges of innovation as it works to engineer and manufacture biological cells at scale. Between its highly automated ...Ginkgo Bioworks stock plunged as much as 24% on Wednesday after a short-seller report from Scorpion Capital alleged that the synthetic biology company is a "Frankenstein mash-up of the worst frauds."Sep 17, 2021 · Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker ... Complete Ginkgo Bioworks Holdings Inc. stock information by Barron's. View real-time DNA stock price and news, along with industry-best analysis.A A. 0. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) insider Reshma P. Shetty has recently sold 37,650 shares of Ginkgo Bioworks stock in a transaction that took place on Wednesday, September 13th. The shares were sold at an average price of $2.04, resulting in a total value of $76,806.00. After the transaction, Shetty now holds …stock market synthetic biology Ginkgo Bioworks The synthetic biology company went public less than a month ago through a $1.6 billion special purpose acquisition company deal, which bestowed upon ...The Ark Invest CEO is also known for having a bit of a contrarian streak, buying shares of stocks right as the market is dumping them, which is exactly what she's doing with Ginkgo Bioworks ( DNA ...Dec 1, 2023 · Many SPACs haven't lived up to their initial hype; unfortunately, Ginkgo hasn't been an exception. When its shares first began trading on the NYSE on Sept. 17, 2021, it opened at a price of $11.15 ...

Wood keeps buying DNA stock despite it being down more than 60% so far this year. Cathie Wood has been adding shares of biotech company Ginkgo Bioworks ( DNA) to her exchange-traded funds (ETFs ...3. Ginkgo Bioworks. Ginkgo Bioworks (DNA 10.85%) is a company that specializes in organisms, and this could be a major business well into the future as these specially engineered organisms help ...Not a stock for the Oracle of Omaha (yet) For the uninitiated, Ginkgo Bioworks is a deeply innovative biotech that specializes in automating the design and cultivation of synthetic bacteria and fungi.Instagram:https://instagram. uber after hourssp500 all time highquarter dollar valueis openai on the stock market With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Oct 06, 2021, 5:24 pm EDT. Shares of Ginkgo Bioworks Holdings closed down almost 12% after Scorpion Capital, a research firm focused on short selling, slammed the company as heavily reliant on ... brokers for mt5the best fha lenders Ginkgo Bioworks ( NYSE: DNA) is a leading synthetic biology company that went public through a SPAC in 2021. A large amount of hype has surrounded Ginkgo due to its ambitions, and it managed to ... china tech Based on short-term price targets offered by eight analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.46. The forecasts range from a low of $1.25 to a high of $7.00 ...Despite the troubled past, Ginkgo ( DNA) acquired Zymergen in October in an all-stock deal valued at $300M, a sharp discount to California- based biotech’s IPO valuation. Announcing the Chapter ...